Compare · HKPD vs NUS
HKPD vs NUS
Side-by-side comparison of Cellyan Biotechnology Co. Ltd (HKPD) and Nu Skin Enterprises Inc. (NUS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HKPD and NUS operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- NUS is the larger of the two at $195.9M, about 49.0x HKPD ($4.0M).
- NUS has been more active in the news (5 items in the past 4 weeks vs 1 for HKPD).
- NUS has more recent analyst coverage (4 ratings vs 0 for HKPD).
- Company
- Cellyan Biotechnology Co. Ltd
- Nu Skin Enterprises Inc.
- Price
- -
- -
- Market cap
- $4.0M
- $195.9M
- 1M return
- -
- -22.55%
- 1Y return
- -
- -57.66%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- 1996
- News (4w)
- 1
- 5
- Recent ratings
- 0
- 4
Nu Skin Enterprises Inc.
Nu Skin Enterprises, Inc. develops and distributes personal care and wellness products worldwide. It provides skin care systems, including ageLOC Me customized skin care and ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products comprising botanical ingredients derived from renewable sources, as well as a range of other cosmetic and personal care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, and LifePak nutritional supplements, as well as other anti-aging nutritional solutions and weight management products. In addition, it is involved in the research and product development of skin care products and nutritional supplements. Further, the company operates retail stores and service centers in Mainland China. It sells its products under the Nu Skin, Pharmanex, and ageLOC brands. The company promotes and sells its products directly, as well as through distributors and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.
Latest HKPD
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- Cellyan Biotechnology Announces a 1-for-20 Reverse Stock Split
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form S-8 filed by Cellyan Biotechnology Co. Ltd
- SEC Form 20-F filed by Cellyan Biotechnology Co. Ltd
- SEC Form NT 20-F filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
Latest NUS
- SEC Form 10-Q filed by Nu Skin Enterprises Inc.
- CORRECTING and REPLACING Nu Skin Enterprises Reports Third Quarter Earnings
- Nu Skin Enterprises Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Nu Skin Enterprises Reports Third Quarter Earnings
- Nu Skin Enterprises Announces Quarterly Dividend
- Nu Skin Enterprises to Announce Third Quarter 2026 Financial Results
- Director Woodbury Edwina D was granted 22 shares, increasing direct ownership by 0.04% to 62,474 units (SEC Form 4)
- Nu Skin Ranked the World’s #1 Company for Beauty and Wellness Device Systems for Third Consecutive Year
- Nu Skin Enterprises Inc. filed SEC Form 8-K: Leadership Update
- SEC Form 10-Q filed by Nu Skin Enterprises Inc.